118th Congress · HOUSE BILLBILL

H.R. 5547 — Maintaining Investments in New Innovation Act

“To amend title XI of the Social Security Act to protect access to genetically targeted technologies.”

Health
Introduced Sep 18, 2023
Last action Dec 17, 2024
Pipeline · Bill → Law
Step 1
Introduced
Sep 18, 2023
Step 2
Referred
E&C · Ways & Means
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Provisions · 2 sections
Timeline · 0 actions